

Guillermo L Chantada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6881641/publications.pdf>

Version: 2024-02-01

160
papers

6,021
citations

70961

41
h-index

98622

67
g-index

168
all docs

168
docs citations

168
times ranked

3784
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging. <i>British Journal of Ophthalmology</i> , 2023, 107, 127-132.	2.1	9
2	Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries. <i>Eye</i> , 2022, 36, 1571-1577.	1.1	9
3	Defining High-risk Retinoblastoma. <i>JAMA Ophthalmology</i> , 2022, 140, 30.	1.4	9
4	Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29568.	0.8	6
5	Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study. <i>Cancer</i> , 2022, 128, 1493-1502.	2.0	17
6	SIOP Strategy 2021-2025: Cure for more, care for all. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29577.	0.8	2
7	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. <i>Journal of Pathology</i> , 2022, , .	2.1	3
8	Treatment of Retinoblastoma: What Is the Latest and What Is the Future. <i>Frontiers in Oncology</i> , 2022, 12, 822330.	1.3	30
9	Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: Implications for retinoblastoma treatment. <i>Experimental Eye Research</i> , 2022, 218, 109026.	1.2	4
10	High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma. <i>Ophthalmology</i> , 2022, 129, 923-932.	2.5	9
11	Subsequent malignant neoplasms in the pediatric age in retinoblastoma survivors in Argentina. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29710.	0.8	6
12	Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma. <i>Ophthalmology</i> , 2022, 129, 933-945.	2.5	8
13	Impact of COVID-19 in pediatric oncology care in Latin America during the first year of the pandemic. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29748.	0.8	5
14	Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). <i>Journal of Clinical Oncology</i> , 2022, 40, 3839-3847.	0.8	11
15	The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. <i>The Lancet Global Health</i> , 2022, 10, e1128-e1140.	2.9	24
16	Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries. <i>British Journal of Ophthalmology</i> , 2021, 105, 1435-1443.	2.1	19
17	Global Retinoblastoma Treatment Outcomes. <i>Ophthalmology</i> , 2021, 128, 740-753.	2.5	40
18	A decision process for drug discovery in retinoblastoma. <i>Investigational New Drugs</i> , 2021, 39, 426-441.	1.2	11

#	ARTICLE	IF	CITATIONS
19	The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28962.	0.8	8
20	Response criteria for intraocular retinoblastoma: RB-RECIST. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28964.	0.8	6
21	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. <i>Ecancermedalscience</i> , 2021, 15, 1187.	0.6	4
22	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. <i>Cancers</i> , 2021, 13, 673.	1.7	9
23	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28963.	0.8	9
24	High prevalence of BRAF V600E in patients with cholestasis, sclerosing cholangitis or liver fibrosis secondary to Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29115.	0.8	0
25	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 332-340.	2.7	83
26	Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG). <i>Cancers</i> , 2021, 13, 3392.	1.7	5
27	COVID-19: Consequences for Children With Cancer in Turkey and Globally. , 2021, 56, 295-299.		9
28	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. <i>Nature Communications</i> , 2021, 12, 5578.	5.8	45
29	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1416-1426.	5.1	93
30	Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. <i>Cancers</i> , 2020, 12, 2714.	1.7	27
31	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28409.	0.8	113
32	Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America. <i>Lancet Oncology</i> , The, 2020, 21, 753-755.	5.1	73
33	A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1733-1746.	2.5	37
34	A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1719-1732.	2.5	36
35	Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. <i>JAMA Ophthalmology</i> , 2020, 138, 569.	1.4	17
36	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37

#	ARTICLE	IF	CITATIONS
37	Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncology, 2020, 6, 685.	3.4	192
38	Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Ophthalmology, 2020, 127, 1549-1557.	2.5	24
39	Retinoblastoma: Metastatic Disease. , 2019, , 249-253.		0
40	Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists. Journal of Global Oncology, 2019, 5, 1-8.	0.5	5
41	Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. Journal of Clinical Oncology, 2019, 37, 2875-2882.	0.8	33
42	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine, 2019, 11, .	5.8	67
43	Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). Pediatric Blood and Cancer, 2019, 66, e27621.	0.8	14
44	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "œAlive, with good vision and no comorbidity" Progress in Retinal and Eye Research, 2019, 73, 100764.	7.3	123
45	Minimally disseminated disease and outcome in overt orbital retinoblastoma. Pediatric Blood and Cancer, 2019, 66, e27662.	0.8	3
46	Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment. British Journal of Haematology, 2019, 185, 1125-1135.	1.2	17
47	Comparison of the pharmacological activity of idarubicin and doxorubicin for retinoblastoma. Pediatric Blood and Cancer, 2019, 66, e27441.	0.8	3
48	Retinoblastoma: An International Perspective. , 2019, , 57-65.		0
49	Survivin is high in retinoblastoma, but what lies beneath?. Journal of AAPOS, 2018, 22, 482.	0.2	1
50	Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina. Pediatric Blood and Cancer, 2018, 65, e27086.	0.8	21
51	Assessment of retinoblastoma RNA reflux after intravitreal injection of melphalan. British Journal of Ophthalmology, 2018, 102, 415-418.	2.1	10
52	The technique of superselective ophthalmic artery chemotherapy for retinoblastoma: The Garrahan Hospital experience. Interventional Neuroradiology, 2018, 24, 93-99.	0.7	11
53	Treatment of Nonmetastatic Unilateral Retinoblastoma in Children. JAMA Ophthalmology, 2018, 136, 747.	1.4	33
54	Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma. British Journal of Ophthalmology, 2018, 102, 1597-1601.	2.1	4

#	ARTICLE	IF	CITATIONS
55	Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27385.	0.8	11
56	OCULAR PHARMACOLOGY OF CHEMOTHERAPY FOR RETINOBLASTOMA. <i>Retina</i> , 2017, 37, 1-10.	1.0	31
57	Second Neoplasms in Children Following a Treatment for Acute Leukemia and/or Lymphoma: 29 Years of Experience in a Single Institution in Argentina. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e406-e412.	0.3	3
58	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. <i>Journal of Controlled Release</i> , 2017, 264, 34-44.	4.8	11
59	Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 574-581.	1.2	0
60	A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26879.	0.8	48
61	Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic) Tj ETQq1 1 0.784314 rgBT /Overlock	0.9	45
62	Beliefs and Determinants of Use of Traditional Complementary/Alternative Medicine in Pediatric Patients Who Undergo Treatment for Cancer in South America. <i>Journal of Global Oncology</i> , 2017, 3, 701-710.	0.5	14
63	An international survey of classification and treatment choices for group D retinoblastoma. <i>International Journal of Ophthalmology</i> , 2017, 10, 961-967.	0.5	30
64	Title is missing!, , 2017, , .		33
65	Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10506-10506.	0.8	20
66	Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina. <i>Ecanermedalscience</i> , 2016, 10, 672.	0.6	9
67	Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery. <i>PLoS ONE</i> , 2016, 11, e0151343.	1.1	14
68	Twenty-Year Collaboration Between North American and South American Retinoblastoma Programs. <i>Journal of Global Oncology</i> , 2016, 2, 347-352.	0.5	9
69	Anaplastic Large Cell Lymphoma in Central America: A Report From the Central American Association of Pediatric Hematology Oncology (AHOPCA). <i>Pediatric Blood and Cancer</i> , 2016, 63, 78-82.	0.8	13
70	Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis. <i>British Journal of Haematology</i> , 2016, 172, 287-290.	1.2	18
71	Sustained-release hydrogels of topotecan for retinoblastoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 146, 624-631.	2.5	16
72	Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. <i>JAMA Ophthalmology</i> , 2016, 134, 1374.	1.4	21

#	ARTICLE	IF	CITATIONS
73	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. <i>Cancer Letters</i> , 2016, 380, 10-19.	3.2	22
74	Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 230-235.	0.6	21
75	Racotumomab for treating lung cancer and pediatric refractory malignancies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 573-578.	1.4	18
76	Improved Outcome and Decreased Morbidity and Mortality Rates of B-Cell Malignancies with Less Intensive Chemotherapy Induction: Experience in a Single Institution. <i>Blood</i> , 2016, 128, 1858-1858.	0.6	2
77	Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells. <i>PLoS ONE</i> , 2016, 11, e0160094.	1.1	18
78	Retinoblastoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15021.	18.1	376
79	A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2120-2124.	0.8	34
80	Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma. , 2015, 56, 4382.		18
81	SIOPâ€PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in lowâ€and middleâ€income settings. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1305-1316.	0.8	73
82	Management of Retinoblastoma in Children: Current Status. <i>Paediatric Drugs</i> , 2015, 17, 185-198.	1.3	31
83	Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. <i>JAMA Ophthalmology</i> , 2015, 133, 805.	1.4	28
84	Improving our understanding of the use of traditional complementary/alternative medicine in children with cancer. <i>Cancer</i> , 2015, 121, 1492-1498.	2.0	11
85	Treatment of Retinoblastoma in 2015. <i>JAMA Ophthalmology</i> , 2015, 133, 1341.	1.4	208
86	Immunoreactivity of the 14F7 Mab raised against <i>N</i>â€Glycolyl <sc>GM</sc>3 Ganglioside in retinoblastoma tumours. <i>Acta Ophthalmologica</i> , 2015, 93, e294-300.	0.6	26
87	Retinoblastoma: International Perspective. , 2015, , 51-60.		1
88	Management of High-Risk Retinoblastoma. <i>Essentials in Ophthalmology</i> , 2015, , 85-96.	0.0	0
89	A population-based study of retinoblastoma incidence and survival in Argentine children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1610-1615.	0.8	38
90	OCULAR PHARMACOLOGY OF TOPOTECAN AND ITS ACTIVITY IN RETINOBLASTOMA. <i>Retina</i> , 2014, 34, 1719-1727.1.0		38

#	ARTICLE	IF	CITATIONS
91	Ophthalmic Artery Microcatheterization for Research Purposes in Pigs. A Technical Note. Journal of Investigative Surgery, 2014, 27, 291-293.	0.6	4
92	Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatric Blood and Cancer, 2014, 61, 821-826.	0.8	32
93	Clinical Pharmacokinetics of Intra-arterial Melphalan and Topotecan Combination in Patients with Retinoblastoma. Ophthalmology, 2014, 121, 889-897.	2.5	45
94	Local and Systemic Toxicity of Intravitreal Melphalan for Vitreous Seeding in Retinoblastoma. Ophthalmology, 2014, 121, 1810-1817.	2.5	147
95	Anterior Segment Invasion in Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2014, 36, e509-e512.	0.3	20
96	Use of intra-arterial chemotherapy for retinoblastoma: results of a survey. International Journal of Ophthalmology, 2014, 7, 726-30.	0.5	39
97	Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Experimental Eye Research, 2013, 108, 103-109.	1.2	42
98	Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. European Journal of Cancer, 2013, 49, 2892-2899.	1.3	26
99	Practical recommendations for the management of children with Endemic Burkitt Lymphoma (BL) in a resource limited setting. Pediatric Blood and Cancer, 2013, 60, 357-362.	0.8	60
100	Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatric Blood and Cancer, 2013, 60, 766-770.	0.8	46
101	Spectrum of <i>RB1</i> Mutations in Argentine Patients: 20-years Experience in the Molecular Diagnosis of Retinoblastoma. Ophthalmic Genetics, 2013, 34, 189-198.	0.5	14
102	Comparison of Staging Systems for Extraocular Retinoblastoma. JAMA Ophthalmology, 2013, 131, 1127.	1.4	29
103	SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatric Blood and Cancer, 2013, 60, 719-727.	0.8	69
104	Management of high-risk retinoblastoma. Expert Review of Ophthalmology, 2012, 7, 61-72.	0.3	2
105	Outcome of Children With Retinoblastoma and Isolated Choroidal Invasion. JAMA Ophthalmology, 2012, 130, 724-9.	2.6	49
106	Early Mortality in Children With Advanced Mature B-cell Malignancies in a Middle-income Country. Journal of Pediatric Hematology/Oncology, 2012, 34, e266-e270.	0.3	12
107	PHARMACOKINETIC ANALYSIS OF TOPOTECAN AFTER SUPERSELECTIVE OPHTHALMIC ARTERY INFUSION AND PERIOULAR ADMINISTRATION IN A PORCINE MODEL. Retina, 2012, 32, 387-395.	1.0	33
108	Clinical Presentation of Retinoblastoma in a Middle-income Country. Journal of Pediatric Hematology/Oncology, 2012, 34, e97-e101.	0.3	19

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic Analysis of Melphalan after Superselective Ophthalmic Artery Infusion in Preclinical Models and Retinoblastoma Patients. , 2012, 53, 4205.		57
110	Retinoblastoma: Lessons and challenges from developing countries. Ellsworth Lecture 2011. Ophthalmic Genetics, 2011, 32, 196-203.	0.5	29
111	Web-based survey of resources for treatment and long-term follow-up for children with brain tumors in developing countries. Child's Nervous System, 2011, 27, 1957-1961.	0.6	21
112	Strategies to manage retinoblastoma in developing countries. Pediatric Blood and Cancer, 2011, 56, 341-348.	0.8	115
113	Is It Pre-Enucleation Chemotherapy or Delayed Enucleation of Severely Involved Eyes With Intraocular Retinoblastoma That Risks Extraocular Dissemination and Death?. Journal of Clinical Oncology, 2011, 29, 3333-3334.	0.8	18
114	Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	45
115	Importance of Multi-lineage Hematologic Involvement and Hypoalbuminemia at Diagnosis in Patients With "Risk-organ" Multi-system Langerhans Cell Histiocytosis. Journal of Pediatric Hematology/Oncology, 2010, 32, e122-e125.	0.3	16
116	Trilateral retinoblastoma: Potentially curable with intensive chemotherapy. Pediatric Blood and Cancer, 2010, 54, 384-387.	0.8	66
117	High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatric Blood and Cancer, 2010, 55, 149-152.	0.8	68
118	Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatric Blood and Cancer, 2010, 55, 60-66.	0.8	51
119	Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. , 2010, 51, 2126.		47
120	Pharmacokinetic analysis of topotecan after intra-vitreous injection. Implications for retinoblastoma treatment. Experimental Eye Research, 2010, 91, 9-14.	1.2	37
121	Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. Molecular Medicine Reports, 2010, 3, 253-9.	1.1	18
122	Pulmonary Manifestations of Hematologic and Oncologic Diseases. , 2009, , 135-169.		0
123	A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma. , 2009, 50, 1492.		48
124	Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatric Blood and Cancer, 2009, 52, 218-222.	0.8	50
125	Familial retinoblastoma in developing countries. Pediatric Blood and Cancer, 2009, 53, 338-342.	0.8	36
126	Some Clinical Findings at Presentation Can Predict High-risk Pathology Features in Unilateral Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2009, 31, 325-329.	0.3	47

#	ARTICLE	IF	CITATIONS
127	Microscopic Scleral Invasion in Retinoblastoma. JAMA Ophthalmology, 2009, 127, 1006.	2.6	32
128	Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients' response. Pediatric Blood and Cancer, 2008, 50, 932-932.	0.8	0
129	World disparities in risk definition and management of retinoblastoma: A report from the International Retinoblastoma Staging Working Group. Pediatric Blood and Cancer, 2008, 50, 692-694.	0.8	52
130	Retinoblastoma: One World, One Vision. Pediatrics, 2008, 122, e763-e770.	1.0	115
131	Outcome of Patients with Retinoblastoma and Postlaminar Optic Nerve Invasion. Ophthalmology, 2007, 114, 2083-2089.	2.5	59
132	Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Ophthalmology, 2007, 114, 1378-1383.	2.5	201
133	Topotecan Vitreous Levels after Periocular or Intravenous Delivery in Rabbits: An Alternative for Retinoblastoma Chemotherapy. , 2007, 48, 3761.		54
134	Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatric Blood and Cancer, 2007, 49, 256-260.	0.8	57
135	Reactivation and risk of sequelae in Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2007, 48, 696-699.	0.8	51
136	Treatment of retinoblastoma: Current status and future perspectives. Current Treatment Options in Neurology, 2007, 9, 294-307.	0.7	75
137	Retinoblastoma: an international perspective. , 2007, , 417-421.		1
138	Staging and grouping of retinoblastoma. , 2007, , 422-427.		7
139	Metastatic retinoblastoma. , 2007, , 484-486.		3
140	An Aggressive Bone Marrow Evaluation Including Immunocytology With GD2 for Advanced Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2006, 28, 369-373.	0.3	27
141	A proposal for an international retinoblastoma staging system. Pediatric Blood and Cancer, 2006, 47, 801-805.	0.8	225
142	Colorectal Carcinoma in Children, Adolescents, and Young Adults. Journal of Pediatric Hematology/Oncology, 2005, 27, 39-41.	0.3	48
143	Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatric Blood and Cancer, 2005, 44, 455-460.	0.8	46
144	Activity of topotecan in retinoblastoma. Ophthalmic Genetics, 2004, 25, 37-43.	0.5	47

#	ARTICLE	IF	CITATIONS
145	Outcome in children with pulmonary Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2004, 43, 765-769.	0.8	74
146	Results of a prospective study for the treatment of retinoblastoma. <i>Cancer</i> , 2004, 100, 834-842.	2.0	69
147	Lack of activity of oral etoposide for relapsed intraocular retinoblastoma. <i>Ophthalmic Genetics</i> , 2004, 25, 25-29.	0.5	6
148	Treatment of overt extraocular retinoblastoma. <i>Medical and Pediatric Oncology</i> , 2003, 40, 158-161.	1.0	111
149	Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in argentina. <i>Medical and Pediatric Oncology</i> , 2003, 41, 488-490.	1.0	12
150	Trisomy 3 in two paediatric post-transplant lymphomas. <i>British Journal of Haematology</i> , 2002, 117, 558-562.	1.2	4
151	Phase II Window of Idarubicin in Children With Extraocular Retinoblastoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1847-1847.	0.8	29
152	Retinoblastoma with low risk for extraocular relapse. <i>Ophthalmic Genetics</i> , 1999, 20, 133-140.	0.5	39
153	Alkalinization and tumor lysis syndrome. , 1999, 32, 156-156.		4
154	Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. <i>Ophthalmic Genetics</i> , 1999, 20, 31-36.	0.5	31
155	LANGERHANS CELL HISTIOCYTOSIS: Retrospective Evaluation of 123 Patients at a Single Institution. <i>Pediatric Hematology and Oncology</i> , 1999, 16, 377-385.	0.3	96
156	Acute myeloid leukemia as a second malignancy: report of 9 pediatric patients in a single institution in Argentina. , 1998, 30, 160-164.		24
157	Results of a BFM-based protocol for the treatment of childhood B-non-Hodgkin's lymphoma and B-Acute lymphoblastic leukemia in Argentina. , 1997, 28, 333-341.		16
158	Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina. , 1997, 29, 544-552.		21
159	Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. <i>Leukemia Research</i> , 1996, 20, 973-981.	0.4	13
160	Children with fever of unknown origin in Argentina. <i>Pediatric Infectious Disease Journal</i> , 1994, 13, 260-263.	1.1	41